Last Price$190.61.0%
Market Cap$10.4B
2.3%
Peers median - 3.2%
6.9%
Peers median - 11.3%
69.2%
Peers median - 25.8%
(14.8%)
Peers median - 10.5%
Competing with MASI
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$10.4B | 5.2 | $139.9 26.6% overvalued | 50.3% | $2,094.4M | $145.3M | 2.3% | 6.9% | 48.0% | (14.8%) | 69.2% | |
$207.3B | 6.9 | $106.1 81.3% overvalued | 41.5% | $8,352.1M | $1,077.2M | 17.2% | 12.9% | 67.5% | 26.8% | 0.0% | |
$66.3B | 6.1 | $262.7 15.0% undervalued | (1.4%) | $20.6B | $2,936.0M | 5.9% | 14.2% | 59.4% | 5.4% | 55.9% | |
$46.6B | 6.4 | $81.3 13.6% overvalued | 9.9% | $9,926.1M | $608.0M | 3.6% | 6.1% | 55.6% | 9.1% | 23.8% | |
$34.6B | 7.6 | $190.6 18.2% overvalued | 29.9% | $4,926.8M | $1,388.4M | 12.9% | 28.2% | 57.9% | 32.9% | 16.0% | |
$18.6B | 5.8 | $92.7 1.2% undervalued | (10.8%) | $3,895.4M | $288.1M | 8.4% | 7.4% | 62.8% | 5.9% | 32.0% | |
$17.9B | 4.7 | $52.7 51.1% undervalued | (16.2%) | $12.9B | $566.0M | (14.0%) | 4.4% | 37.1% | (1.5%) | 191.5% | |
$16.9B | 6.1 | $152.8 33.0% overvalued | (36.3%) | $2,893.1M | $276.4M | (1.9%) | 9.6% | 34.6% | 18.6% | 11.3% | |
$14.7B | 7.3 | $131.7 108.2% undervalued | (15.2%) | $4,038.9M | $1,135.5M | 1.8% | 28.1% | 56.2% | 13.2% | 1.0% | |
$9,757.8M | 6.5 | $174.5 19.0% undervalued | 4.2% | $3,582.9M | $349.2M | 2.7% | 9.7% | 48.7% | 12.0% | 27.7% | |
$8,979.7M | 5.9 | $29.8 80.8% overvalued | (20.6%) | $616.0M | $131.3M | (8.0%) | 21.3% | 46.9% | (1.2%) | 33.3% |
Compare MASI Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Masimo CorporationMASI
5.2x
0.6%
(42.5%)
4.0%
Median Peer Set
5.2x
3.4%
23.0%
10.4%
Alcon Inc.ALC
5.0x
8.5%
182.9%
10.3%
AptarGroup, Inc.ATR
2.9x
2.7%
30.2%
10.5%
Baxter International Inc.BAX
2.3x
(69.5%)
(100.0%)
(6.9%)
Becton, Dickinson and CompanyBDX
4.1x
4.2%
18.3%
8.4%
The Cooper Companies, Inc.COO
5.4x
8.4%
32.2%
10.1%
Hologic, Inc.HOLX
3.2x
(0.0%)
81.1%
19.6%
Intuitive Surgical, Inc.ISRG
24.3x
17.2%
27.7%
27.8%
Repligen CorporationRGEN
14.4x
(21.1%)
(80.9%)
5.6%
ResMed Inc.RMD
7.1x
10.9%
13.4%
21.8%
West Pharmaceutical Services, Inc.WST
5.8x
(1.9%)
(15.5%)
17.0%
Compare MASI Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Masimo Corporation (MASI) revenue growth compare to peers and the industry?
Masimo Corporation (MASI) revenue growth is 2.3%, compared to the peers' median of 3.2%.
2. How does Masimo Corporation (MASI) Free Cash Flow (FCF) margin compare to peers and the industry?
Masimo Corporation (MASI) FCF margin is 6.9%, compared to the peers' median of 11.3%.
3. How does Masimo Corporation (MASI) Total Debt to Equity ratio compare to peers and the industry?
Masimo Corporation (MASI) Total Debt to Equity ratio is 69.2%, compared to the peers' median of 25.8%.
4. How does Masimo Corporation (MASI) ROIC (Return on Invested Capital) compare to peers and the industry?
Masimo Corporation (MASI) ROIC is (14.8%), compared to the peers' median of 10.5%.